Skip to NavigationSkip to content


AstraZeneca to retire MedImmune brand amid restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

The announcement comes just a month after AstraZeneca announced organisational changes which will see the creation of therapy area specific R&D units.

AstraZeneca acquired MedImmune in 2007, running the firm as a separate biologics unit. However the restructuring will see the company integrated into AstraZeneca’s new R&D units.

Brandicourt set to continue Sanofi restructure

Sanofi reception
Olivier Brandicourt is restructuring the Sanofi business

Sanofi chief executive Olivier Brandicourt is considering sales or spin-offs of a number of the company’s divisions, as part of a wider five-year strategic plan, it is reported.

Brandicourt took the helm at Sanofi in February and just a few months later set about restructuring the global business to make ‘necessary changes’ – including creating three new business units that w

Lundbeck sheds 1,000 jobs in £284 million restructure

Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus its business more on its mental illness treatments.

The Danish firm says the cuts are “in order to significantly improve profitability and improve the company's value creation”. It hopes it can reduce its total cost base by nearly 3 billion Danish Krone (£284 million) by 2017.

Lundbeck will restructure its headquarter functions and commercial operations in Europe and other markets, cutting 1,000 employees from its workforce.

GSK sees further US job losses following Novartis deal

GSK image

Hundreds more jobs are at risk within GlaxoSmithKline as the fallout from the company’s asset-swapping deal with Novartis continues.

Staff in the UK firm’s consumer health division in Pittsburgh, Pennsylvania, have been told their jobs are at risk – after the firm decided to close the office where 275 members of the workforce are based.

Merck planning more manufacturing cutbacks?

Merck image

Merck & Co has said it intends to make additional reductions to its manufacturing network, although the pace of restructuring will be slower than in the period following its takeover of Schering-Plough in 2009.

Merck's chief financial officer Peter Kellogg said on the firm's latest results call that the group operated 93 facilities around the world when it completed the merger across its pharmaceuticals, veterinary and consumer health businesses.

‘Challenging’ Europe slows GSK

GSK image

‘Challenging’ economic conditions in Europe are among the factors GlaxoSmithKline is blaming for its sluggish performance, with turnover worldwide down 3% from 2011 to £26.4 billion last year.

Pharma accounted for £17.9 billion of this, a year-on-year drop of 2%, with ‘weaker than expected’ sales in Europe - and the US business also flat - down 7% and 4% respectively.

The manufacturer said pressure from austerity measures in Europe, including price cuts, parallel trade and generic substitution, was hampering performance.

Sanofi to cut 900 jobs in France

Sanofi is to cut 900 jobs in its French operations by 2015 – fewer than expected after widespread speculation this summer that 2,500 posts could be chopped.

However the future of its Toulouse research facility, which has around 600 staff, is up in the air with Sanofi saying its function “remains to be specified” – although the manufacturer insists that the number of its sites in France will remain the same.

The ex-CEO's Job Blog - part 1

Published on 03/09/12 at 12:00am

I have seen a lot in my healthcare career. Been round the block more than twice, as they say.

I have been fired, promoted and downsized (OK, made redundant). I have experienced abject failure and thankfully, some degree of success. I have helped a few on their way up and also ‘encouraged’ one or two to find less demanding roles in other industries.

Merck Serono tweaks Swiss restructuring plans

Workers 'flash mob' outside Merck Serono HQ
Workers 'flash mob' outside Merck Serono HQ

Merck KGaA has finalised the restructuring plans at Swiss drugs unit Merck Serono, confirming that it intends to close its Geneva headquarters and manufacturing facility at Coinsins.

The revised plan is pretty close to the original framework revealed in April, with around 500 jobs set to go as a result of the closures and 750 staff due to be switched to sites in Switzerland (Aubonne), Merck's other headquarters in Germany (Darmstadt), the US (Boston) and China (Beijing).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches